Biocon arm Syngene International announced today the acquisition of its first biologics facility in the USA from Emergent ...

Syngene International acquires US manufacturing facility, expanding bioreactor capacity and global service capabilities for pharmaceutical innovation.

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...

Biocon Biologics on Thursday said it has tied up with not-for-profit generic drug and pharmaceutical firm Civica, Inc to expand access and affordability of Insulin Aspart in the US.